Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2403917 | 0.94 | RXFP1 (0.35) | RXFP1ALOX5APFEN1 | |
| SCHEMBL2401682 | 0.91 | TRPV3 (0.34) | RXFP1ALOX5APFEN1 | |
| SCHEMBL3563428 | 0.91 | KDM4E (0.45) | RXFP1PTGS2PTGS1 | |
| SCHEMBL3559279 | 0.91 | GSK3B (0.38) | RXFP1PTGS2PTGS1 | |
| SCHEMBL3559682 | 0.90 | KDM4E (0.40) | RXFP1 | |
| SCHEMBL2399946 | 0.90 | PFKFB3 (0.39) | — | |
| SCHEMBL3566655 | 0.89 | ALOX5AP (0.38) | RXFP1ALOX5APFEN1 | |
| SCHEMBL3560038 | 0.88 | ABL1 (0.37) | RXFP1ALOX5APFEN1PTGS2 | |
| SCHEMBL3556405 | 0.87 | PTGS2 (0.36) | RXFP1ALOX5APFEN1PTGS2PTGS1 | |
| SCHEMBL2401529 | 0.85 | NPC1 (0.43) | PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415380-B2 | Pyridine and pyrimidine derivatives as MGLUR2 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-20110263615-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | GATTI MCARTHUR SILVIA | 2011-10-27 | — | — | US | disclosed |
| US-8012986-B2 | Pyridine and pyrimidine derivatives as MGLUR2 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-09-06 | — | — | US | disclosed |
| EP-2142527-B1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-12-29 | — | — | EP | disclosed |
| EP-2142527-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2010-01-13 | — | — | EP | disclosed |
| US-20080280924-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | HOFFMAN-LA ROCHE, INC. | 2008-11-13 | — | — | US | disclosed |
| WO-2008119689-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263615-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | GRM2, GRIN2B, GRM1 | RXFP1 216/4885ALOX5AP 2101/4885FEN1 4729/4885 |
| US-20080280924-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | GRM2, GRIN2B, GRM1 | RXFP1 216/4885ALOX5AP 2101/4885FEN1 4729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.